Active Entries
- 1: Poking my head back in
- 2: A guide to Dreamwidth moods and customization
- 3: The Soseono Masterpost
- 4: Signal Boost: Easier Dreamwidth Posts with Markdown: the sequel
- 5: Signal Boost bookmarklet with user name tags for more sites
- 6: Reasons I Love Avatar 2: Relationships (Part 2 of 2)
- 7: On being a Christian atheist
- 8: Micah speculation
- 9: Policing and woobiefication: two sides of the same coin
- 10: Frustrations, mom posting, workstation
Style Credit
- Base style: Bases by
- Theme: Velvet Steel by
Expand Cut Tags
No cut tags
no subject
Date: 2015-11-05 04:44 pm (UTC)My thesis is a pretty obscure area even for international law scholars, but it's basically about a fair price on nature: Genetic resources such as wild plants or microbes. Under the Convention on Biological Diversity most of the countries around the world agreed that genetic resource-rich countries (mostly though not all in the global South) should get a fair and equitable share when companies from biotechnology-rich countries (in the global North) cash out on the former's genetic resources. When a Swiss pharmaceutical company makes profits off Tamiflu whose active ingredient is fennel and whose process is based on traditional Chinese medicine, for instance. The problem is what this fair and equitable share is. Genetic resource users and providers are supposed to agree on this by contract, but countries are also obligated to make the benefit sharing fair and equitable. So the central question is, how to regulate these contracts to make sure they provide for fair and equitable benefit sharing? And the heart of that comes down to, what does "fair and equitable" mean in the first place in this context? That's what I'm trying to define and what my graduation hinges on.